Results 71 to 80 of about 73,785 (303)

MANAGEMENT OF PATIENTS ON ANTICOAGULANT THERAPY UNDERGOING DENTAL SURGICAL PROCEDURES. Review Article. [PDF]

, 2013
Dental treatment performed in patients receiving oral anticoagulant drug therapy is becoming increasingly common in dental offices.The aim of oral anticoagulant therapy is to reduce blood coagulability to an optimal therapeutic range within which the ...
Atanaska Dinkova, Delyan Delev, Donka G. Kirova   +2 more
core   +1 more source

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience

American Journal of Hematology, EarlyView.
ABSTRACT Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a
Bruno Fattizzo, Elisa Sambruna, Yoshitaka Miyakawa, Marc Michel, Carlo Visco, Michael Fillitz, George Kannourakis, Maria Bruna Greve, Moritz Kleemiss, Johan Cid, Andrea Patriarca, Laura Pavan, Arbana Dizdari, Nilla Maschio, Antonella Sau, Cinzia Bitetti, Riccardo Mario Colombo, Luigi Curreli, Dorela Lame, Uros Markovic, Fabrizio Pappagallo, Giacinto Luca Pedone, Davide Rapezzi, Vincenzo Sammartano, Nicola Tumedei, Antonio Giovanni Solimando, Jalink Marit, Luana Fianchi, Jahanzaib Khwaja, Antonio De Vivo, Francesco Lanza, Fabrizio Vianello, Esther N. Oliva, Catherine Broome, Francesco Passamonti, Ulrich Jaeger, Bernd Jilma, Guillaume Moulis, Wilma Barcellini   +38 more
wiley   +1 more source

Direct Oral Anticoagulant Drugs in Dental Clinical Practice

Acta Medica Martiniana, 2017
The direct oral anticoagulant drugs (DOAC) are generally safe and effective in several clinical settings including acute venous thromboembolic disease, prophylaxis in the postoperative setting, prevention of thromboembolism in patients with non-valvular ...
Stasko J., Stasko J., Janickova M., Mikuskova K., Malachovsky I., Gengelova P., Kasaj M., Smatanova M., Statelova D.   +8 more
doaj   +1 more source

Safe chest tube placement in a patient with tension pneumothorax receiving rivaroxaban therapy for non-valvular atrial fibrillation

Monaldi Archives for Chest Disease, 2020
The number of patients treated with direct oral anticoagulants is increasing worldwide. Although bleeding complications associated with direct oral anticoagulants are lower than those associated with vitamin K antagonists, the increased number of ...
Alessandro Cipriano, Matteo Parollo, Ester Taurino, Elena Venturi, Massimo Santini   +4 more
doaj   +1 more source

Direct Oral Anticoagulants: A Quick Guide [PDF]

European Cardiology Review, 2017
Vitamin K antagonists, such as warfarin, have been the anticoagulants of choice for many years for patients with AF and other thrombotic conditions. The introduction of direct oral anticoagulants (DOACs) as alternatives represents a major advance in anticoagulation.
Sikorska, Julia, Uprichard, James
openaire   +2 more sources

In‐Hospital Bleeding Outcomes of Myocardial Infarction in the Era of Warfarin and Direct Oral Anticoagulants for Atrial Fibrillation in the United States: A Report From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background We sought to examine patient characteristics, peri‐infarction invasive and pharmacologic management, and in‐hospital major bleeding in myocardial infarction patients with atrial fibrillation or flutter, based on home anticoagulant use. Methods
Dmitriy N. Feldman, Tracy Y. Wang, Anita Y. Chen, Rajesh V. Swaminathan, Luke K. Kim, S. Chiu Wong, Robert M. Minutello, Geoffrey Bergman, Harsimran S. Singh, Christopher Madias   +9 more
doaj   +1 more source

Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range [PDF]

, 2016
BACKGROUND: The benefits and harms of oral anticoagulation (OAC) therapy in patients with only one stroke risk factor (i.e. CHA2DS2-VASc= 1 in males, or 2 in females) has been subject of debate.
Lip, Gregory Y. H., Proietti, Marco
core   +2 more sources

Effect of Laser Posterior Nasal Neurolysis for the Treatment of Chronic Rhinitis: A Randomized Controlled Trial

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background To determine the safety and efficacy of laser ablation of the posterior nasal nerve (PNN) for the treatment of chronic rhinitis. Methods This study was a single‐center, prospective, single‐blinded, randomized sham‐controlled trial. Patients with a 24‐h reflective Total Nasal Symptom Score (rTNSS) ≧ 5, rhinorrhea ≧ 2, and congestion ≧
Jyun‐Yi Liao, En‐Ying Wang, Ying‐Shuo Hsu, Ming‐Shao Tsai, Cheng‐Jung Wu, Chia‐Hao Chang, Yi‐Li Hwang, Han‐Lo Teng, Jun‐Wei Hsieh, Chien‐Yu Huang   +9 more
wiley   +1 more source

Development and Validation of a Machine Learning Model to Predict Oral Anticoagulant Use in Stroke From Prothrombin Time–International Normalized Ratio and Activated Partial Thromboplastin Time

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Timely recognition of oral anticoagulant use is critical in acute stroke but is often hampered by impaired consciousness and unavailable medication history.
Gaku Fujiwara, Yoshinari Nagakane, Nobukuni Murakami, Eiichi Suehiro, Naoya Hashimoto, Sohei Yoshimura, Kazunori Toyoda, Yohei Okada   +7 more
doaj   +1 more source

DOAC‐Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples

Research and Practice in Thrombosis and Haemostasis, 2021
Background The use of direct oral anticoagulants (DOACs) is a convenient therapeutic option for patients at risk of thrombosis. DOACs interfere with clot‐based testing for the identification of lupus anticoagulant antibodies (LACs) in patients with ...
Steven Andrew Baker, Jing Jin, Christopher Pfaffroth, Trang Vu, James L. Zehnder   +4 more
doaj   +1 more source